Earnings visibility is difficult due to the multi-faceted nature of Sagent's generic drug business, however, CEO Jeffrey Yordon says he anticipates a strong first quarter after seeing sales rise 20% in Q4. He expects Sagent to launch between 12 and 16 new products this year after launching a dozen last year. Yordon also says the company's new Chinese plant is already FDA-approved and manufacturing products, and he has high expectations for Sagent's research center in Chengdu China.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

If you liked this article you might like

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Changing Landscape for Generic-Drug Makers Creates Opportunities

Sagent Pharmaceuticals (SGNT) Soared Today on Nichi-Iko Deal

3 Stocks You Might Want to Sell Now

Sagent Pharmaceuticals (SGNT) Flagged As Strong On High Volume